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Background: Glycogen synthase kinase 3β (GSK3β) is a 
ubiquitous serine/threonine kinase that is regulated by ser-
ine phosphorylation at 9. Recent studies have reported the 
beneficial effects of a number of the pharmacological 
GSK3β inhibitors in rodent models of septic shock. Since 
most of the GSK3β  inhibitors are targeted at the ATP-bind-
ing site, which is highly conserved among diverse protein kin-
ases, the development of novel non-ATP competitive 
GSK3β  inhibitors is needed. Methods: Based on the unique 
phosphorylation motif of GSK3β, we designed and gen-
erated a novel class of GSK3β inhibitor (GSK3i) peptides. 
In addition, we investigated the effects of a GSK3i peptide 
on lipopolysaccharide (LPS)-stimulated cytokine production 
and septic shock. Mice were intraperitoneally injected with 
GSK3i peptide and monitored over a 7-day period for 
survival.  Results: We first demonstrate its effects on 
LPS-stimulated pro-inflammatory cytokine production in-
cluding interleukin (IL)-6 and IL-12p40. LPS-induced IL-6 and 
IL-12p40 production in macrophages was suppressed when 
macrophages were treated with the GSKi peptide. 
Administration of the GSK3i peptide potently suppressed 
LPS-mediated endotoxin shock. Conclusion: Collectively, we 
present a rational strategy for the development of a ther-
apeutic GSK3i peptide. This peptide may serve as a novel 




G l y c o g e n  s y n t h a s e  k i n a s e  3  ( G S K 3 )  i s  a  u b i q u i t o u s  s e r -
ine/threonine  kinase  that  is  regulated  by  serine  phosphor-
ylation at 21 in GSK3α and 9 in GSK3β (1-3). GSK3 phos-
phorylates a broad range of substrates such as glycogen syn-
thase  (4),  nuclear  factor  of  activated  T-cells  (NFATc)  (5), 
cAMP  response  element  binding  (CREB)  (6),  c-Jun  (7)  and 
c-Myc  (8),  and  also  inactivates  many  of  these  substrates. 
Through this activity, GSK3 regulates many cellular functions, 
including  glycogen  metabolism,  cell-cycle  control  and  cell 
proliferation  (3,9).  Among  the  GSK3  isoforms,  α and  β, 
GSK3β gained prominence as a potential drug target in vari-
ous disease areas including type 2 diabetes (10,11), Alzhei-
mer’s  disease  (12),  mood  disorders  (13)  and  cancer  (14). 
Recently,  GSK3β was  also  identified  as  a  regulator  of  the 
i m m u n e  s y s t e m ,  s u g g e s t i n g  i t  m i g h t  b e  a n  a t t r a c t i v e  t h e r -
apeutic  target  in  inflammatory  and  autoimmune  diseases 
(15-18). 
    Due  to  the  growing  evidence  of  GSK3β a s  a  p o t e n t i a l  
therapeutic  target  in  multiple  diseases  (19,20),  several  ap-
proaches such as high-throughput screening, virtual computer 
simulations, and structure-based drug design have been used 
to develop GSK3β kinase inhibitors (21). Most of these in-
hibitors are a class of ATP-competitive inhibitors. However, 
a major drawback to the use of the inhibitors is their limited 
specificity,  and  therefore  there  is  a  concern  that  such  in-
hibitors  exert  undesired  side  effects  (22-25).
    To overcome these issues, we developed a cell-permeable 
peptide, the GSK3β inhibitor (GSKi) peptide. We hypothe-
sized that small unique peptides derived from the N-terminal 
phosphorylation  motif  of  GSK3β containing  serine  9  may Effects of GSK3β Inhibitor Peptide on Septic Shock
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Figure 1. Structure of the GSKi peptide conjugated with the Hph-1 
protein transduction domain. Amino acid sequences corresponding to
residues 3∼12 of GSK3β were chosen for the design of a GSKi 
peptide. The serine 9 residue, which can be phosphorylated by 
PKB/Akt, is highlighted in bold. The control peptide contains 11-mer 
of the protein transduction domain.
Figure 2. The GSKi peptide decreased pro-inflammatory cytokines production after LPS stimulation. BMDMs were pre-incubated for 2 hours 
with medium only and either 10μM SB216763 or 5μM GSK3i peptide, and then stimulated with 1μg/ml LPS for 20 hours. Cell-free supernatants 
were analyzed by ELISA for production of pro-inflammatory cytokines; IL-6 (A) or IL-12p40 (B). Data represent mean±s.d. and are representative
of at least three experiments.
serve  as  a  pseudo-substrate  of  GSK3β in  cells  (26-28).
    In this study, we have investigated the effects of a novel 
GSK3i  peptide  in  a  LPS-induced  septic  shock  model.  We 
found that inhibition of GSK3β by the inhibitor peptide de-
creased LPS-mediated pro-inflammatory cytokine production. 
In  addition,  administration  of  the  GSK3i  peptide  protected 
mice  from  LPS-induced  endotoxin  shock.  Therefore,  the 
GSK3i peptide may be useful in the development of selective 
therapeutic agents for the treatment of septic shock and other 
related  inflammatory  diseases.
MATERIALS AND METHODS
Cell culture
Murine  bone  marrow-derived  macrophages  (BMDMs)  were 
obtained  from  the  femur  of  6∼8  week-old  C57BL/6  male 
m i c e .  B o n e  m a r r o w  c e l l s  w e r e  f l u s h e d  o u t  f r o m  t h e  b o n e  
marrow cavity, suspended in DMEM (Hyclone) that was sup-
plemented with 20% heat-inactivated FBS, 100 units/ml pen-
icillin,  100μg / m l  s t r e p t o m y c i n .  A f t e r  1  d a y ,  n o n - a d h e r e n t  
cells were cultured in the presence of 10 ng/ml recombinant 
human M-CSF (R&D Systems). After 7 days, a homogeneous 
population  of  adherent  macrophages  was  obtained.
Peptide synthesis
Cell-permeable  peptides  were  synthesized  by  Peptron 
(Daejeon, Korea). Peptides were purified by preparative re-
v e r s e - p h a s e  H P L C  a n d  w e r e  m o r e  t h a n  9 5 %  p u r e  w i t h  t h e 
expected  amino  acid  composition  and  mass  spectra. 
Immediately before use, the peptides were dissolved in phos-
phate  buffered  saline  (PBS)  to  prepare  stock  solutions  that 
were  between  5  and  10  mM.
Measurement of cytokines
The level of mouse interleukin (IL)-6 and IL-12p40 in culture 
supernatants  and  sera  were  measured  using  enzyme-linked 
immunosorbent assay (ELISA) kits from BD biosciences (San 
Jose, CA, USA) according to the manufacturer’s instructions.Effects of GSK3β Inhibitor Peptide on Septic Shock
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Figure 3. The GSK3i peptide protected mice from LPS-induced 
endotoxin shock. 25 mg/kg of the GSK3 inhibitor SB216763 (n=15)
or 30 mg/kg of the GSK3i peptide (n=15) were administered
intraperitoneally to mice before injection of 15 mg/kg of the E.coli 
K235 LPS insult, which is the lethal dose (LD100). Sham-immunized
mice were given only PBS containing 0.1% DMSO (n=4). LPS control
(n=15). Administration of the GSK3 inhibitor SB216763 or GSK3i 
peptide protected mice from an LD100 of LPS given therapeutically.
Survival of mice following LPS challenge was monitored for 7 days.
Figure 4. In vivo IL-6 in plasma, measured by ELISA 12 hours after
mice were given an LD100 of LPS. Sham-immunized mice were given 
only PBS containing 0.1% DMSO (n=3). n=12 for LPS only, 
SB216763, and GSKi peptide, respectively.
Endotoxin shock model
All animal study protocols were approved by the Animal Care 
Committee of Ewha Laboratory Animal Genomics Center. The 
endotoxin shock model used in this study has been described 
previously (15). In brief, male C57BL/6 mice (6∼8 weeks of 
age;  18∼20  g  body  weight)  were  injected  intraperitoneally 
with an LD100 (10μg/ml) of E. coli K235 LPS (Sigma) in 200 
μl of PBS containing 0.1% DMSO. Mice survival was moni-
tored  over  a  7-day  period. 
RESULTS
Inhibitory effect of the GSKi peptide on LPS-induced 
pro-inflammatory cytokine production
We designed a cell-permeable GSKi peptide spanning the ser-
ine 9 phosphorylation motif of GSK3β that was fused with 
recently characterized cell-permeable sequences derived from 
the human transcription factor Hph-1 (Fig. 1) (29,30). Since 
GSK3β is known key regulator of pro-inflammatory cytokine 
production (16), we examined the ability of the GSKi peptide 
to regulate cytokine production in response to LPS stimula-
tion.  BMDMs  from  male  6∼8  week-old  mice  were  pre-in-
cubated for 2 hours with either 5μM GSKi peptide or 10μM 
SB216763 as a positive control, and then the cells were stimu-
lated  with  1μg/ml  LPS  for  20  hours.  The  control  peptide 
containing the cell-permeable sequences only did not affect 
cytokine production stimulated by LPS (data not shown). As 
s h o w n  i n  F i g .  2 ,  t h e  p r e s e n c e  o f  t h e  G S K 3 i  p e p t i d e  w a s  
shown  to  attenuate  pro-inflammatory  cytokine  production; 
IL-6 and IL-12p40. These inhibitory effects were comparable 
to that of SB216763 which is a well-characterized pharmaco-
logical inhibitor of GSK3. These results demonstrate that the 
GSKi peptide can regulate LPS-mediated pro-inflammatory cy-
tokine  production.
The GSKi peptide protects mice from endotoxin 
shock
To test the therapeutic potential of the GSKi peptide on septic 
shock, the effects of the peptide on an experimental LPS-in-
duced  endotoxin  shock  model were  investigated.  Mice  that 
were given 30 mg/kg of the GSKi peptide before receiving 
a  100%  lethal  dose  (LD100)  of  LPS  showed  significantly  im-
proved survival, compared with the control group given LPS 
( F i g .  3 ) .  T h i s  p r o t e c t i v e  e f f e c t  w a s  c o m p a r a b l e  t o  t h a t  o f  
SB216763.  The  control  peptide  did  not  affect  LPS-induced 
septic  shock  (data  not  shown).
    Next,  we  examined whether GSK3β inhibition  regulated 
the pro-inflammatory cytokine production in mice given an 
LD100 of LPS. As shown in Fig. 4, we found that the serum 
level of the pro-inflammatory cytokine IL-6 was significantly 
reduced in LPS-challenged mice given the GSK3i peptide rela-Effects of GSK3β Inhibitor Peptide on Septic Shock
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tive to that of the control mice given LPS. Thus, these results 
demonstrate that a cell-permeable inhibitor peptide that tar-
gets GSK3β may be useful in the treatment of septic shock.
DISCUSSION
In this study, we present a new strategy for developing a nov-
el inhibitor peptide that targets GSK3β. Our study has shown 
that the peptide motif spanning serine 9 of GSK3β blocks 
LPS-induced cytokine production and septic shock. The cen-
tral role of the GSK3β pathway in innate immune responses 
has  been  well  documented  (31).  Specifically,  it  has  been 
shown that GSK3β is involved in the PI3K/Akt pathway and 
mediates  cytokine  production  in  TLR  signaling  (15).  More-
over,  many  reports  have  elucidated  important  roles  for  the 
GSK3β in immune diseases such as arthritis, colitis, multiple 
sclerosis  and  sepsis  (32,33)  suggesting  that  GSK3  might  be 
an  attractive  therapeutic  target  in  inflammatory  diseases.  In 
t h i s  r e g a r d ,  o u r  s t u d i e s  s u g g e s t  t h a t  t h e  G S K i  p e p t i d e  m a y 
be  used  as  a  novel  tool  for  studying  GSK3  inhibition.
    The exact mechanism of how the GSK3i peptide regulates 
i n f l a m m a t o r y  r e s p o n s e  s u c h  a s  c y t o k i n e  p r o d u c t i o n  i s  n o t  
fully understood. In resting cells, GSK3 is highly active, but 
its enzyme activity can be inhibited by the PI3-kinase-depend-
ent  pathway  in  response  to  various  ligands  stimulation 
(34-36). It has been well established that PKB/Akt is respon-
sible for the direct phosphorylation of GSK3β on the N-ter-
minal serine 9 residue (37,38). After serine 9 phosphorylation, 
the phosphorylated N-terminal residues of GSK3β inhibit the 
enzyme by binding to the  active  site as  a  pseudo-substrate 
(26-28). Since the GSKi peptide contains a serine 9 residue 
that can be phosphorylated by PKB/Akt in cells, it may act 
as a pseudo-substrate that binds in the active site of GSK3β 
and inhibits its enzyme activity. Consistent with our data, a 
phosphopeptide corresponding to residue 7-14 of GSK3β in-
hibited GSK3 activity in vitro, whereas the nonphsphorylated 
peptide  did  not  (27,34).
    The development of bioactive peptides as therapeutic alter-
natives  offers  novel  exciting  approaches  for  target-selective 
pharmacotherapy (39,40). The in vivo pharmacodynamics of 
the GSKi peptide was not detemined in this study. However, 
our data demonstrated that the GSKi peptide acted  in vivo 
to protect mice against LPS-induced shock. Such phenomen-
on indicates that a more detailed assessment of the in vivo 
d e l i v e r y  a n d  p h a r m a c o k i n e t i c  p r o f i l e s  o f  t h e  G S K i  p e p t i d e  
may lead to the design of effective therapeutic reagents di-
rected  against  septic  shock.
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